Paradigm Biocapital Advisors LP
- SEC CIK
- 0001855655
- Latest filing
- Aug 14, 2026
Holdings in Q1 2022
Holdings as of Mar 31, 2022, filed May 16, 2022. Long positions only; changes compare share counts with Q4 2021.
- Positions
- 25
- +1 vs. Q4 2021
- Portfolio value
- $378.2M
- +$28.0M (+8.0%) vs. Q4 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ASNDAscendis Pharma A/S | SPONSORED ADR | 321,621 | $37.7M | 10.0% | +103,463+47.4% | Added | History |
| GBTGlobal Blood Therapeutics, Inc. | COM | 966,827 | $33.5M | 8.9% | +186,347+23.9% | Added | History |
| ARVNArvinas, Inc. | COM | 491,333 | $33.1M | 8.7% | +222,814+83.0% | Added | History |
| LEGNLegend Biotech Corp | SPONSORED ADS | 831,728 | $30.2M | 8.0% | +445,761+115.5% | Added | History |
| SRRASierra Oncology, Inc. | COM NEW | 771,314 | $24.7M | 6.5% | +296,369+62.4% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,256,051 | $23.2M | 6.1% | +47,000+3.9% | Added | History |
| INCYIncyte Corp | COM | 234,419 | $18.6M | 4.9% | +234,419 | New | History |
| ISEEIVERIC bio, Inc. | COM | 910,416 | $15.3M | 4.1% | +94,835+11.6% | Added | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 907,428 | $15.1M | 4.0% | +63,423+7.5% | Added | History |
| IMCRImmunocore Holdings plc | ADS | 499,190 | $14.9M | 3.9% | +364,941+271.8% | Added | History |
| HZNPHorizon Therapeutics Public Ltd Co | SHS | 136,243 | $14.3M | 3.8% | +136,243 | New | History |
| UTHRUnited Therapeutics Corp | COM | 75,635 | $13.6M | 3.6% | +75,635 | New | History |
| ZNTLZentalis Pharmaceuticals, Inc. | COM | 287,577 | $13.3M | 3.5% | −12,857−4.3% | Reduced | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 701,356 | $12.2M | 3.2% | +248,265+54.8% | Added | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 499,496 | $12.1M | 3.2% | +240,750+93.0% | Added | History |
| OYSTOyster Point Pharma, Inc. | COM | 987,698 | $11.5M | 3.0% | +683,460+224.6% | Added | History |
| PRTAProthena Corp Public Ltd Co | SHS | 267,946 | $9.80M | 2.6% | +267,946 | New | History |
| KYMRKymera Therapeutics, Inc. | COM | 227,034 | $9.61M | 2.5% | +101,176+80.4% | Added | History |
| MRTXMirati Therapeutics, Inc. | COM | 98,383 | $8.09M | 2.1% | −161,732−62.2% | Reduced | History |
| MRUSMerus N.V. | COM | 249,738 | $6.60M | 1.7% | +249,738 | New | History |
| VORVor Biopharma Inc. | COM | 894,404 | $5.40M | 1.4% | +265,062+42.1% | Added | History |
| ESPREsperion Therapeutics, Inc. | COM | 1,157,246 | $5.37M | 1.4% | +317,989+37.9% | Added | History |
| FULCFulcrum Therapeutics, Inc. | COM | 212,961 | $5.04M | 1.3% | +212,961 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 336,229 | $3.02M | 0.8% | +336,229 | New | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 783,445 | $1.82M | 0.5% | +238,057+43.6% | Added | – |
Sold out since Q4 2021 (6)
Positions held at the end of Q4 2021 that are gone from this filing.
| Security | Class | Shares in Q4 2021 | Value in Q4 2021 | % of portfolio in Q4 2021 | History |
|---|---|---|---|---|---|
| ARNAArena Pharmaceuticals Inc | COM NEW | 251,777 | $23.4M | 6.7% | History |
| SGENSeagen Inc. | COM | 100,687 | $15.6M | 4.4% | History |
| ARGXArgenx SE | SPONSORED ADR | 42,050 | $14.7M | 4.2% | History |
| INSMINSMED Inc | COM PAR $.01 | 394,358 | $10.7M | 3.1% | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 167,824 | $9.25M | 2.6% | History |
| ENTAEnanta Pharmaceuticals Inc | COM | 75,507 | $5.65M | 1.6% | History |